Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-IMI 1: Imipenem/Cilastatin/Relebactam vs Colistin in Resistant Infections
NCT02452047Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of relebactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI) and 1 more (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Favorable Overall Response (FOR) at Day 30 and Percentage of Participants With ≥1 Adverse Events (AEs) at Day 35. Started Aug 2015; status: completed.
02
Drugs
relebactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT02452047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452047.